A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients

Wajeh Y Qunibi, Carlos Martinez, Mark Smith, Joseph Benjamin, Antoinette Mangione, Simon D Roger, Wajeh Y Qunibi, Carlos Martinez, Mark Smith, Joseph Benjamin, Antoinette Mangione, Simon D Roger

Abstract

Background: Iron deficiency is a common cause of anaemia and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in non-dialysis-dependent chronic kidney disease (ND-CKD) patients. Current intravenous iron agents cannot be administered in a single high dose because of adverse effects. Ferric carboxymaltose, a non-dextran parenteral iron preparation, can be rapidly administered in high doses.

Methods: This open-label trial randomized 255 subjects with glomerular filtration rates ≤ 45 mL/min/1.73 m(2), haemoglobin ≤ 11 g/dL, transferrin saturation ≤ 25%, ferritin ≤ 300 ng/mL, and stable ESA dose to either intravenous ferric carboxymaltose 1000 mg over 15 min (with up to two additional doses of 500 mg at 2-week intervals) or oral ferrous sulphate 325 mg thrice daily for a total of 195 mg elemental iron daily for 56 days.

Results: In the modified intent-to-treat population, the proportion of subjects achieving a haemoglobin increase ≥ 1 g/dL at any time was 60.4% with ferric carboxymaltose and 34.7% with oral iron (P < 0.001). At Day 42, mean increase in haemoglobin was 0.95 ± 1.12 vs 0.50 ± 1.23 g/dL (P = 0.005), mean increase in ferritin was 432 ± 189 ng/mL vs 18 ± 45 ng/mL (P < 0.001) and mean increase in transferrin saturation was 13.6 ± 11.9% vs 6.1 ± 8.1% (P < 0.001). Treatment-related adverse events were significantly fewer with ferric carboxymaltose than with oral iron (2.7% and 26.2%, respectively; P < 0.0001).

Conclusions: We conclude that 1000 mg ferric carboxymaltose can be rapidly administered, is more effective and is better tolerated than oral iron for treatment of iron deficiency in ND-CKD patients.

Figures

Fig. 1
Fig. 1
Patient disposition.
Fig. 2
Fig. 2
Percent of subjects (mITT population) achieving Hb ≥ 1 g/dL at any study time point (last observation carried forward). Hb, haemoglobin; mITT, modified intention-to-treat.
Fig. 3
Fig. 3
Mean (SE) for (A) haemoglobin (g/dL), (B) ferritin (ng/mL) and (C) TSAT (%) values by treatment group over time. FCM, ferric carboxymaltose; TSAT, transferrin saturation. *Significantly higher compared with baseline value in the FCM group. P-values are from unpaired two-sample t-tests, assuming equal variances for differences in change from baseline, and are for differences between the FCM and oral iron groups at various study points.

References

    1. Hsu CY, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002;13:2783–2786.
    1. Gotloib L, Silverberg D, Fudin R, et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161–167.
    1. Post JB, Wilkes BM, Michelis MF. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin. Int Urol Nephrol. 2006;38:719–723.
    1. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234–238.
    1. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791–798.
    1. Aggarwal HK, Nand N, Singh S, et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003;51:170–174.
    1. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530–538.
    1. DeVita MV, Frumkin D, Mittal S, et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol. 2003;60:335–340.
    1. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694–1699.
    1. Taylor JE, Peat N, Porter C, et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079–1083.
    1. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070–2076.
    1. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 6. Association of Level of GFR with Complications in Adults. Guideline 12. Association of Level of GFR with Indices of Functioning and Well-Being. (21 May 2010, last accessed date)
    1. Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999;69:S61–S66.
    1. Van Wyck DB, Roppolo M, Martinez CO, et al. For the United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846–2856.
    1. Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100:c55–c62.
    1. Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26:445–454.
    1. Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (≥250 mg) administration. Am J Kidney Dis. 2003;41:651–657.
    1. Fishbane S. Safety in iron management. Am J Kidney Dis. 2003;41:S18–S26.
    1. Nissenson AR, Charytan C. Controversies in iron management. Kidney Int. 2003;64:S64–S71.
    1. Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject(r)): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert. 2009;23:11–16.
    1. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182–1192.
    1. van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007;110:267–278.
    1. Srigiridhar K, Nair KM, Subramanian R, et al. Oral repletion of iron induces free radical mediated alterations in the gastrointestinal tract of rat. Mol Cell Biochem. 2001;219:91–98.
    1. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001;16:967–974.
    1. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19:1599–1605.
    1. Bailie GR, Clark JA, Lane CE, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant. 2005;20:1443–1449.
    1. Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378–382.
    1. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33:464–470.
    1. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001;38:988–991.
    1. Bastani B, Jain A, Pandurangan G. Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. Nephrology (Carlton) 2003;8:8–10.
    1. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503–2509.
    1. Ferrlecit® [package insert] Corona, CA: Watson Pharma, Inc.; 2001.
    1. Venofer® [package insert] Shirley, NY: American Regent Laboratories, Inc.; 2000.
    1. Mohammed S, Knoll S, van AA III, et al. Cefotetan-induced hemolytic anemia causing severe hypophosphatemia. Am J Hematol. 1994;46:369–370.
    1. Sahara N, Tamashima S, Ihara M. Hereditary spherocytosis associated with severe hypophosphatemia in patients recovering from aplastic crisis. Rinsho Ketsueki. 1998;39:386–391.
    1. Steiner M, Steiner B, Wilhelm S, et al. Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25:1015–1016.
    1. Campos MS, Barrionuevo M, Alferez MJ, et al. Interactions among iron, calcium, phosphorus and magnesium in the nutritionally iron-deficient rat. Exp Physiol. 1998;83:771–781.
    1. McLane JA, Fell RD, McKay RH, et al. Physiological and biochemical effects of iron deficiency on rat skeletal muscle. Am J Physiol. 1981;241:C47–C54.
    1. Schouten BJ, Hunt PJ, Livesey JH, et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332–2337.
    1. Szczech LA, Bregman DB, Harrington RA, et al. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. Nephrol Dial Transplant. 2010;25:2368–2375.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi